Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating)'s share price gapped down before the market opened on Thursday . The stock had previously closed at $14.59, but opened at $12.68. Janux Therapeutics shares last traded at $12.68, with a volume of 10 shares trading hands.
Janux Therapeutics Price Performance
The stock's fifty day simple moving average is $13.41 and its 200 day simple moving average is $13.66. The firm has a market capitalization of $525.33 million, a P/E ratio of -9.61 and a beta of 1.66.
Get
Janux Therapeutics alerts:
Janux Therapeutics (NASDAQ:JANX – Get Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.04). Janux Therapeutics had a negative net margin of 809.63% and a negative return on equity of 15.10%. The company had revenue of $2.37 million during the quarter. As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.74 EPS for the current fiscal year.
Institutional Investors Weigh In On Janux Therapeutics
Several large investors have recently added to or reduced their stakes in the stock. American International Group Inc. boosted its holdings in shares of Janux Therapeutics by 25.3% in the first quarter. American International Group Inc. now owns 8,813 shares of the company's stock worth $126,000 after buying an additional 1,782 shares during the period. Amalgamated Bank acquired a new stake in shares of Janux Therapeutics in the 1st quarter valued at $28,000. Goldman Sachs Group Inc. grew its holdings in Janux Therapeutics by 21.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 17,934 shares of the company's stock worth $257,000 after acquiring an additional 3,186 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Janux Therapeutics by 34.9% in the 1st quarter. JPMorgan Chase & Co. now owns 17,926 shares of the company's stock valued at $256,000 after purchasing an additional 4,638 shares during the period. Finally, Rhumbline Advisers raised its position in shares of Janux Therapeutics by 46.9% during the first quarter. Rhumbline Advisers now owns 16,216 shares of the company's stock worth $233,000 after purchasing an additional 5,179 shares during the period. 66.07% of the stock is owned by institutional investors and hedge funds.
Janux Therapeutics Company Profile
(Get Rating)
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Featured Stories
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- PENN Entertainment Stock is Reset and Ready to Rebound
- NVIDIA: A Top Choice In Bifurcated Chip Market?
- 3 Payroll Software Makers Set For Growth In 2023
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
